|
1
|
Teachey DT, Rheingold SR, Maude SL, et al:
Cytokine release syndrome after blinatumomab treatment related to
abnormal macrophage activation and ameliorated with
cytokine-directed therapy. Blood. 121:5154–5157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanofi Canada: Thymoglobulin®
(Anti-thymocyte globulin [rabbit]) product monograph. http://products.sanofi.ca/en/thymoglobulin.pdfJan
25–2015
|
|
3
|
Mahmud N, Klipa D and Ahsan N: Antibody
immunosuppressive therapy in solid-organ transplant: Part I. MAbs.
2:148–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shanmugam G: Vasoplegic syndrome - the
role of methylene blue. Eur J Cardiothorac Surg. 28:705–710. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Landry DW and Oliver JA: The pathogenesis
of vasodilatory shock. N Engl J Med. 345:588–595. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedrich M, Bräuer A, Tirilomis T, Lotfi
S, Mielck F and Busch T: Methylene blue administration in severe
systemic inflammatory response syndrome (SIRS) after thoracic
surgery. Ann Thorac Cardiovasc Surg. 8:306–310. 2002.PubMed/NCBI
|
|
7
|
Stawicki SP, Sims C, Sarani B, Grossman MD
and Gracias VH: Methylene blue and vasoplegia: who, when, and how?
Mini Rev Med Chem. 8:472–490. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Argenziano M, Chen JM, Cullinane S, et al:
Arginine vasopressin in the management of vasodilatory hypotension
after cardiac transplantation. J Heart Lung Transplant. 18:814–817.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taylor KM: SIRS - the systemic
inflammatory response syndrome after cardiac operations. Ann Thorac
Surg. 61:1607–1608. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Downing SW and Edmunds LH Jr: Release of
vasoactive substances during cardiopulmonary bypass. Ann Thorac
Surg. 54:1236–1243. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flynn BC and Sladen RN: The use of
methylene blue for vasodilatory shock in a pediatric lung
transplant patient. J Cardiothorac Vasc Anesth. 23:529–530. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Levin RL, Degrange MA, Bruno GF, et al:
Methylene blue reduces mortality and morbidity in vasoplegic
patients after cardiac surgery. Ann Thorac Surg. 77:496–499. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beasley D and McGuiggin M: Interleukin 1
activates soluble guanylate cyclase in human vascular smooth muscle
cells through a novel nitric oxide-independent pathway. J Exp Med.
179:71–80. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mekontso-Dessap A, Houël R, Soustelle C,
Kirsch M, Thebért D and Loisance DY: Risk factors for
post-cardiopulmonary bypass vasoplegia in patients with preserved
left ventricular function. Ann Thorac Surg. 71:1428–1432. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Robin JK, Oliver JA and Landry DW:
Vasopressin deficiency in the syndrome of irreversible shock. J
Trauma. 54(Suppl): S149–S154. 2003.PubMed/NCBI
|
|
16
|
Boyle EM Jr..Pohlman TH, Johnson MC and
Verrier ED: Endothelial cell injury in cardiovascular surgery: the
systemic inflammatory response. Ann Thorac Surg. 63:277–284.
1997.PubMed/NCBI
|
|
17
|
Kwok ES and Howes D: Use of methylene blue
in sepsis: A systematic review. J Intensive Care Med. 21:359–363.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cauwels A, Janssen B, Buys E, Sips P and
Brouckaert P: Anaphylactic shock depends on PI3K and eNOS-derived
NO. J Clin Invest. 116:2244–2251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Montrucchio G, Alloatti G and Camussi G:
Role of platelet-activating factor in cardiovascular
pathophysiology. Physiol Rev. 80:1669–1699. 2000.PubMed/NCBI
|
|
20
|
Neugut AI, Ghatak AT and Miller RL:
Anaphylaxis in the United States: an investigation into its
epidemiology. Arch Intern Med. 161:15–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gomes WJ, Carvalho AC, Palma JH, et al:
Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg
(Torino). 39:619–623. 1998.PubMed/NCBI
|
|
22
|
Schulz R, Nava E and Moncada S: Induction
and potential biological relevance of a Ca(2+)-independent nitric
oxide synthase in the myocardium. Br J Pharmacol. 105:575–580.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cremer J, Martin M, Redl H, et al:
Systemic inflammatory response syndrome after cardiac operations.
Ann Thorac Surg. 61:1714–1720. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brown SG: Cardiovascular aspects of
anaphylaxis: implications for treatment and diagnosis. Curr Opin
Allergy Clin Immunol. 5:359–364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kemp SF and Lockey RF: Anaphylaxis: a
review of causes and mechanisms. J Allergy Clin Immunol.
110:341–348. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takakura K, Mizogami M and Fukuda S:
Protamine sulfate causes endothelium-independent vasorelaxation via
inducible nitric oxide synthase pathway. Can J Anaesth. 53:162–167.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Viaro F, Dalio MB and Evora PR:
Catastrophic cardiovascular adverse reactions to protamine are
nitric oxide/cyclic guanosine monophosphate dependent and
endothelium mediated: should methylene blue be the treatment of
choice? Chest. 122:1061–1066. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Donati A, Conti G, Loggi S, et al: Does
methylene blue administration to septic shock patients affect
vascular permeability and blood volume? Crit Care Med.
30:2271–2277. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thiemermann C, Szabó C, Mitchell JA and
Vane JR: Vascular hyporeactivity to vasoconstrictor agents and
hemodynamic decompensation in hemorrhagic shock is mediated by
nitric oxide. In: Proc Natl Acad Sci USA. 90. pp. 267–271. 1993;
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peer G, Itzhakov E, Wollman Y, et al:
Methylene blue, a nitric oxide inhibitor, prevents haemodialysis
hypotension. Nephrol Dial Transplant. 16:1436–1441. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guttmann RD, Caudrelier P, Alberici G and
Touraine JL: Pharmacokinetics, foreign protein immune response,
cytokine release, and lymphocyte subsets in patients receiving
thymoglobuline and immunosuppression. In: Transplant Proc. 29. pp.
24S–26S. 1997; View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jeyarajah DR and Thistlethwaite JR Jr.:
General aspects of cytokine-release syndrome: timing and incidence
of symptoms. In: Transplant Proc. 25(Suppl 1): pp. 16–20. 1993;
PubMed/NCBI
|
|
33
|
Radhakrishnan J and Cohen DJ:
Cytokine-release syndrome: general risk-factor modification -
preparation of high-risk patients for use of OKT3. In: Transplant
Proc. 25(Suppl 1): pp. 60–62. 1993; PubMed/NCBI
|
|
34
|
Rosenzweig EB, Starc TJ, Chen JM, et al:
Intravenous arginine-vasopressin in children with vasodilatory
shock after cardiac surgery. Circulation. 100(Suppl): II182–II186.
1999.PubMed/NCBI
|
|
35
|
Torgersen C, Dünser MW, Wenzel V, et al:
Comparing two different arginine vasopressin doses in advanced
vasodilatory shock: a randomized, controlled, open-label trial.
Intensive Care Med. 36:57–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dellinger RP, Levy MM, Rhodes A, et al:
Surviving Sepsis Campaign Guidelines Committee including the
Pediatric Subgroup: Surviving sepsis campaign: international
guidelines for management of severe sepsis and septic shock: 2012.
Critical Care Med. 41:580–637. 2013. View Article : Google Scholar
|
|
37
|
Alexander JH, Reynolds HR, Stebbins AL, et
al: TRIUMPH Investigators: Effect of tilarginine acetate in
patients with acute myocardial infarction and cardiogenic shock:
the TRIUMPH randomized controlled trial. JAMA. 297:1657–1666. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grubb KJ, Kennedy JL, Bergin JD, Groves DS
and Kern JA: The role of methylene blue in serotonin syndrome
following cardiac transplantation: a case report and review of the
literature. J Thorac Cardiovasc Surg. 144:e113–e116. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Licker M, Diaper J, Cartier V, et al:
Clinical review: management of weaning from cardiopulmonary bypass
after cardiac surgery. Ann Card Anaesth. 15:206–223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sloan EP, Koenigsberg MD, Philbin NB and
Gao W: DCLHb Traumatic Hemorrhagic Shock Study Group; European HOST
Investigators: Diaspirin cross-linked hemoglobin infusion did not
influence base deficit and lactic acid levels in two clinical
trials of traumatic hemorrhagic shock patient resuscitation. J
Trauma. 68:1158–1171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Leyh RG, Kofidis T, Strüber M, et al:
Methylene blue: the drug of choice for catecholamine-refractory
vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg.
125:1426–1431. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fischer GW and Levin MA: Vasoplegia during
cardiac surgery: current concepts and management. Semin Thorac
Cardiovasc Surg. 22:140–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
